Last deal

$9M

Amount

Venture - Series Unknown

Stage

02.08.2017

Date

3

all rounds

$9.8M

Total amount

date founded

Financing round

General

About Company
Indalo Therapeutics is a biotechnology company developing a drug for fibrotic diseases.

Industry

Sector :

Subsector :

Also Known As

Antegrin Therapeutics

founded date

01.01.2013

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The company is developing a biopharmaceutical therapy that targets integrin antagonists for fibrotic diseases such as NASH and IPF. Their lead drug candidate, IDL-2965, has shown antifibrotic efficacy in multiple animal models of disease in vital organ systems. Indalo's R&D leadership team has a history of developing and approving Esbriet® for IPF at InterMune, and their founding scientists have decades of experience in developing integrin antagonists. The company has received funding from marquee investors Atlas Venture and F-Prime.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Cincera Therapeutics

Cincera Therapeutics

Cincera Therapeutics is a biotechnology company developing drugs to treat metabolic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

Dandenong Rd, Melbourne VIC, Australia

total rounds

3

total raised

$6.17M
Phanes Therapeutics

Phanes Therapeutics

Phanes Therapeutics is a biotech company that develops therapeutics for solid tumors and eye diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

San Diego, CA, USA

total rounds

2

total raised

$40M
NovelMed Therapeutics

NovelMed Therapeutics

NovelMed Therapeutics develops transformative treatments for orphan and non-orphan diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Biopharma, Health Care

Location

Cleveland, OH, USA

total rounds

1

total raised

$1.43M
Abbisko Therapeutics

Abbisko Therapeutics

Abbisko Therapeutics develops small molecule drugs for cancer and other diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Shanghai, China

total rounds

4

total raised

$263M

Financials

Funding Rounds
3
3

Number of Funding Rounds

$9.8M

Money Raised

Their latest funding was raised on 02.08.2017. Their latest investor BioGenerator. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
06.10.2015
$800K
02.04.2013
1
Cultivation Capital

Cultivation Capital

Cultivation Capital is a venture capital firm that invests in early-stage technology startups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

St. Louis, MO, USA

count Of Investments

206

count Of Exists

26
BioGenerator

BioGenerator

BioGenerator provides seed investment to startup bioscience companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

St. Louis, MO, USA

total rounds

2

total raised

$750K

count Of Investments

70

count Of Exists

5
Co-Investors
Investors
5
2

Number of lead investors

5

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Seed
Yes
Venture - Series Unknown
No
Venture - Series Unknown
BioGenerator

BioGenerator

BioGenerator provides seed investment to startup bioscience companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

St. Louis, MO, USA

total rounds

2

total raised

$750K

count Of Investments

70

count Of Exists

5
Cultivation Capital

Cultivation Capital

Cultivation Capital is a venture capital firm that invests in early-stage technology startups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

St. Louis, MO, USA

count Of Investments

206

count Of Exists

26
Argonautic Ventures

Argonautic Ventures

Argonautic Ventures is a venture capital firm that invests in emerging and mature industries to help transform their markets.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Software

Location

Grand Cayman, Cayman Islands

count Of Investments

64

count Of Exists

8

People

Founders
3

Robert Karr

Robert Karr has broad experience in the drug discovery and development process, including discovery/preclinical research, IND preparation, interactions with the FDA, the design and conduct of clinical trials, and investor relations. He currently serves as CSO of Tioma Therapeutics and previously served as President & CEO of Indalo (then called Antegrin Therapeutics) from 2012-2015. Prior roles have included President of Idera Pharmaceuticals, Senior Vice President of Strategic Management at Pfizer, and Vice President of Research and Development Strategy at Warner-Lambert. Dr. Karr received his B.S. (Honors) from Southwestern University in 1971 and his M.D (with highest honors) from the University of Texas Medical Branch in 1975.

current job

Indalo Therapeutics
Indalo Therapeutics

count Of Investments

1

Robert Karr

David Griggs
David Griggs

David Griggs

Dr. Griggs is a scientific expert in the field of integrin biology with over 20 years of experience managing drug research programs at large pharmaceutical companies (Searle, Pharmacia, and Pfizer) and in a university-based translational pharmacology center (the Center for World Health & Medicine at Saint Louis University). He has led teams that designed and implemented nearly two dozen in vitro integrin functional assays as well as diverse in vivo studies to evaluate efficacy, pharmacology, and safety of RGD peptidomimetic integrin antagonists. Dr. Griggs has authored more than 20 peer-reviewed scientific publications and holds several issued and pending U.S. patents. He received a B.S. degree in Biological Sciences from Northern Kentucky University and M.S. and Ph.D. degrees in Microbiology from the University of Illinois at Urbana-Champaign, and he completed postdoctoral studies in the Department of Genetics at Washington University in St. Louis.

current job

Indalo Therapeutics
Indalo Therapeutics

organization founded

2

David Griggs

Peter Ruminski
Peter Ruminski

Peter Ruminski

Peter Ruminski is a Instructor in Medicine, Division of Oncology at Washington University School of Medicine. He Attended Saint Louis University.

current job

Indalo Therapeutics
Indalo Therapeutics

organization founded

2

Peter Ruminski

Employee Profiles
8
Karl Kossen

Karl Kossen

SVP & Translational Science

Williamson Z. Bradford

CMO & Managing Director

Peter Ruminski

Peter Ruminski

Co-Founder and Scientific Advisor

David Griggs

David Griggs

Co-Founder & Scientific Advisor

Robert Karr

Founder, Chief Executive Officer & President

Ramachandran Radhakrishnan

Sr. VP of Pharmaceutical Development

Activity

Recent News
0